|

Arlocabtagene Autoleucel Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Arlo-cel, BMS-986393, CC-95266,, GPRC5D CAR T cells

Pipeline

Phase 2: 1

Top Sponsors

  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1

Indications

  • Multiple Myeloma1
  • Cancer1

Birmingham, Alabama1 trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.